ID
30264
Beschrijving
https://clinicaltrials.gov/show/NCT00989664 Independent Response Evaluation, Oncologist's Assessment Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Link
https://clinicaltrials.gov/show/NCT00989664
Trefwoorden
Versies (1)
- 25-05-18 25-05-18 -
Houder van rechten
GlaxoSmithKline (GSK)
Geüploaded op
25 mei 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664
Independent Response Evaluation, Oncologist's and Joint Assessment
Similar models
Independent Response Evaluation, Oncologist's and Joint Assessment
C0259990 (UMLS CUI-2)
C0220825 (UMLS CUI-3)
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0376298 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C0259990 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C0376298 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C0259990 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C1514693 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])